Therefore, we consider that individuals affected by TSC2 c.700–701 del mutation could exhibit a high variability in clinical findings and further studies are needed to identify a key mechanism underlying the therapeutic effect of everolimus on TSC symptoms with ASD. This evidence concerns the gene TSC2 and tuberous sclerosis.